A role of c-Abl in prostate cancer progression has been demonstrated due to its ability to phosphorylate a Wiskott-Aldrich syndrome protein family, member 3 (WASF3), a protein that controls cellular motility and invasion and is upregulated in advanced metastatic PCa [20]. Here, WAS is linked to prostate carcinoma.